Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

NCT ID: NCT07132515

Last Updated: 2025-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-15

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis HCC - Hepatocellular Carcinoma Portal Vein Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anticoagulant in cirrhosis with HCC

HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Group Type EXPERIMENTAL

Enoxaparin, warfarrin, or apixaban

Intervention Type DRUG

Enoxaparin, warfarrin, or apixaban

Anticoagulant in Cirrhosis without HCC

Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Group Type EXPERIMENTAL

Enoxaparin, warfarrin, or apixaban

Intervention Type DRUG

Enoxaparin, warfarrin, or apixaban

No anticoagualnt in Cirrhosis with or without HCC

cirrhotic patients with thrombosis with or without HCC not on anticoagulant

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enoxaparin, warfarrin, or apixaban

Enoxaparin, warfarrin, or apixaban

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B

Exclusion Criteria

* Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mansoura University Hospitals

Al Mansurah, Dakahlia Governorate, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dalia Elsayed Ganady, MBBS

Role: CONTACT

+201095529264

Hatem Elalfy, PhD

Role: CONTACT

+201224790518

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dalia E Tawfik

Role: primary

+20 1095529264

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS.23.07.2479

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.